PMC8382945_01
Pathological slice of undifferentiated pleomorphic sarcoma. Arrows indicate that the tumor cells have obvious nuclear atypia and pathological nuclear mitosis. (A) 20X HE stain, (B) 40X HE stain.
fsurg-08-693774-g0001.jpg
PMC8382945_01_fsurg-08-693774-g0001.jpg
F1
The above findings met the diagnostic criteria of (skull base) UPS (Figures 1A,B).
Skull base MRI in May, 2018 (Before the operation combined with carbon-ion radiotherapy): (A) MR images in transection. (B) MR images in coronal plane; (C) MR images in sagittal plane. The cross location denotes the recurring tumor. Skull base MRI in March, 2019 (After the operation combined with carbon-ion radiotherapy): (D) MR images in transection; (E) MR images in coronal plane; (F) MR images in sagittal plane. The cross location denotes no recurrent tumor.
fsurg-08-693774-g0002.jpg
PMC8382945_01_fsurg-08-693774-g0002.jpg
F2
The size of lesion had no significant change as compared with before chemotherapy (Figure 2). T2 abnormal signals in left middle ear and mastoid process, thickened mucosa in bilateral maxillary sinus and ethmoid sinus as well as left sphenoid sinus, a cerebral spinal fluid (CSF)-like signal shadow in sellar region, and compression-caused flattened pituitary. Tumor relapse was considered (Figures 2A-C). In March 2019, brain MRI reexamination showed no recurrent tumor lesion (Figures 2D-F).